SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout
Shares of SELLAS Life Sciences climbed in after-hours action Tuesday, following the company’s update that its Phase 3 REGAL trial in acute myeloid leukemia has now logged 78 out of the 80 patient deaths required for the final analysis. In this pivotal study, patient death is the event that triggers the survival analysis.